Heron Therapeutics, Inc. · NASDAQ:HRTX
Heron Therapeutics — Corporate Update (September 2022)
22 slides from Heron Therapeutics's corporate update, Sep 19, 2022
Slide 1: APONVIE (HTX-019) FDA Approval
APONVIE™ (HTX-019) FDA Approval September 19, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this presentation, and involve substantial risks a
Slide 3: Heron Pipeline
Heron Pipeline US FDA Approved for postsurgical analgesia for up to 72 hours* ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Acute Care CINV: Chemotherapy-induced nausea and vomiting. PONV: postoperative nausea and vomiting. SUSTOL® (granisetron) extended-release injection is indica
Slide 4: Is Heron's 4th Drug Approval and an Ideal Strategic Fit
Is Heron’s 4th Drug Approval and an Ideal Strategic Fit INDICATIONS AND USAGE APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Limitations of Use APONVIE has not been studied for the treatment of established nausea and vomiting. The recommended dose in a
Slide 5: Aprepitant Reduced Proportion of Patients Vomiting Through 48 Hours vs. IV Ondansetron
Aprepitant Reduced the Proportion of Patients Vomiting Through 48 hours by 15.2% (p<0.001*) vs. IV Ondansetron (SOC) Aprepitant also significantly delayed the time to first vomiting episode compared with ondansetron Diemunsch P. Br J Anesth. 2007:202-11. *Unadjusted p-value Please See IMPORTANT SAFE
Slide 6: Aprepitant Reduced Proportion of Patients Vomiting Through 48 Hours by 17.7%
Aprepitant Reduced the Proportion of Patients Vomiting Through 48 hours by 17.7% (p<0.001*) vs. IV Ondansetron (SOC) Aprepitant also significantly delayed the time to first vomiting episode compared with ondansetron. *Published results from Gan TJ, et al. Ambul Anesth. 2007; 1082-89. *Unadjusted p-v
Slide 7: 2020 Cochrane Meta-Analysis: Aprepitant Most Effective Drug Approved for PONV
Meta-analysis included 282 studies with 50,812 participants and 65 treatments (28 single agents, 36 drug combinations and placebo) 2020 Cochrane Meta-Analysis Concluded That Aprepitant is Most Effective Drug Approved for PONV* *Weibel S, Rücker G, Eberhart LHJ, Pace NL, Hartl HM, Jordan OL, et al. C
Slide 8: Drug Levels Associated with ≥97% Receptor Occupancy Occur Faster With APONVIE
Drug Levels Associated with ≥97% Receptor Occupancy Occur Much Faster With APONVIE 30-Second IV Push Than with Oral Aprepitant >97% receptor occupancy 90% receptor occupancy ~4-fold higher peak levels with APONVIE are projected to quickly achieve ≥97% receptor occupancy in the brain while patient is
Slide 9: Why Generic Fosaprepitant is not Used for PONV
Why Generic Fosaprepitant is not Used for PONV Fosaprepitant is poorly tolerated when administered through peripheral veins with up to 40% infusion site reactions reported 1, so it was never developed nor approved for PONV The 20-30 minute infusion required for fosaprepitant is inconvenient for PONV
Slide 10: Postoperative Nausea and Vomiting (PONV) Market Opportunity
Postoperative Nausea and Vomiting (PONV) Market Opportunity Please see IMPORTANT SAFETY INFORMATION at the end of this presentation
Slide 11: APONVIE – The Next Big Opportunity at Heron
Large market potential Addressable market = 69M procedures* Significant Unmet Need Convenient, more effective and longer lasting treatments are needed Synergies with Heron commercial organization Majority of same ZYNRELEF target accounts and audiences (ASA) Existing positive experience with CINVANTI
Slide 12: Robust Market Research Was Conducted with HCPs
Robust Market Research was Conducted with > 700 HCPs Leading 3rd party conducted a comprehensive survey on the PONV opportunity and APONVIE Demand This market research along with other surveys serve as the basis for: Market size and anti-emetic usage Segmentation strategy HCP preference share Formul
Slide 13: APONVIE Target Market Opportunity
APONVIE Target Market Opportunity ~ 36 Million Procedures in Patients at Moderate to High Risk for PONV* Source: DRG / Clarivate PONV Demand Study (Dec. 2021) * 2023 Procedure projections Apfel Risk Score ~ 17M High Risk Patients % PONV Patient Risk ~ 19M Moderate Risk Patients Low Moderate High 25%
Slide 14: APONVIE Opportunity
APONVIE Opportunity ~ 38M Annual Procedures* Receive Prophylaxis for PONV ~12M High to Moderate Risk Patients Currently Not Receiving Prophylaxis* Source: DRG / Clarivate PONV Demand Study (Dec. 2021) * 2023 Procedure projections Overall, prophylaxis for PONV is currently administered in 56% of pati
Slide 15: Fourth Consensus Guidelines for Management of PONV
“In this iteration of the PONV guideline, one of the major changes is that we now recommend the use of multimodal prophylaxis in patients with one or more risk factors”. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting1 1Gan TJ, Belani KG, Bergese S, et al. Anesth
Slide 16: APONVIE Key Attributes: One Push to Prevent PONV
APONVIE Key Attributes One Push to Prevent PONV References: 1. Diemunsch P, Apfel C, Gan TJ, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin. 2007;23(10):2559-2565. doi:10.1185/0300799
Slide 17: APONVIE Attributes Resulted in High Physician Preference Share
Source: DRG/Clarivate Claims Analysis, PONV Demand Study (Dec 2021) Preference Share by Risk Type APONVIE Attributes Resulted in High Physician Preference Share Which Grows as Patient PONV Risk Increases Overall Ave Overall Ave Overall Ave Please see IMPORTANT SAFETY INFORMATION at the end of this p
Slide 18: APONVIE is a 30-Second IV Push; Oral Aprepitant Volume Growing
APONVIE is a 30-second IV push with therapeutic levels associated with ≥97% receptor occupancy achieved within 5 minutes and lasts for 48 hours Oral aprepitant was taken 1 to 3 hours prior to induction of general anesthesia in clinical trials and does not reach maximum concentration until 3 hours af
Slide 19: PONV is a Large Market Opportunity
PONV is a large market opportunity with 36 million annual procedures in patients at moderate to high risk for PONV and ~12M high to moderate risk patients currently not receiving prophylaxis Significant Advantages with Unmet Needs Aprepitant is the most effective approved antiemetic, alone or in com
Slide 20: Establish Heron as a Leader in Acute Care
Establish Heron as a Leader in Acute Care References: 1. ZYNRELEF [package insert]. San Diego, CA: Heron Therapeutics Inc; 2021. 2. Viscusi E, Gimbel JS, Pollack RA, et al. Reg Anesth Pain Med. 2019;44(7):700-706. 3. Viscusi E, Minkowitz H, Winkle P, et al. Hernia. 2019;23(6):1071-1080. 4. APONVIE (
Slide 21: Important Safety Information
APONVIE should not be used: if you are allergic to aprepitant or any of the ingredients in APONVIE if you are taking pimozide APONVIE may cause serious side effects. Tell your doctor or nurse right away if you have any of these signs or symptoms of an allergic reaction: trouble breathing or swallowi
Slide 22: Important Safety Information (continued)
Women who use birth control medicines containing hormones to prevent pregnancy (birth control pills, skin patches, implants, and certain IUDs) should also use back-up methods of birth control (such as condoms and spermicides) for 1 month after receiving APONVIE. Before you receive APONVIE, tell your
Heron Therapeutics — Corporate Update (September 2022) on 6ix